<DOC>
	<DOCNO>NCT02042183</DOCNO>
	<brief_summary>A study efficacy safety Lubiprostone pediatric subject age ≥ 6 Years &lt; 18 year diagnose Functional Constipation</brief_summary>
	<brief_title>Efficacy Safety Lubiprostone Pediatric Subjects Aged ≥ 6 Years &lt; 18 Years With Functional Constipation</brief_title>
	<detailed_description>To assess efficacy , safety , pharmacokinetics ( PK ) oral lubiprostone 12 24 mcg capsule dose twice daily ( BID ) ( base subject body weight baseline ) compare match placebo BID , administer orally 12 week pediatric subject functional constipation .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Medicallyconfirmed diagnosis Functional Constipation per Rome III Diagnostic Criteria Childhood Functional Constipation At least 6 year age less 18 year age time randomisation Only stable dose selective serotonin reuptake inhibitor ( SSRIs ) , serotoninspecific reuptake inhibitor ( SNRIs ) , monoamine oxidase inhibitor ( MAO ) inhibitor allow subject take antidepressant Any gastrointestinal ( GI ) condition , constipation and/or irritable bowel syndrome ( IBS ) , affect GI motility defecation Untreated faecal impaction time screen Medical/surgical condition might interfere absorption , distribution , metabolism , excretion study medication</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>